HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy for recurrent malignant glioma: an interim report on survival.

Abstract
We present interim survival data for a group of 83 adult patients with recurrent malignant glioma treated by implanting stimulated autologous lymphocytes into the tumour bed following surgical debulking. The patients were treated 6 months or more prior to data analysis. Fifty-nine patients were male and 24 female. The mean age for the entire group was 48.4 years and the mean Karnofsky rating (KR) was 67.2. Eight of the patients had grade II tumours, 33 had grade III tumours and 42 had grade IV tumours. Statistical analysis focuses on tumour grade, KR and patient age, factors that have been shown to affect survival in previous studies. Multifactorial analyses are employed to identify interrelationships among factors related to survival. Seven patients (8%) did not respond to immunotherapy, 76 (92%) had a good initial response. Twenty-five patients (30.1%) are living and 18 (22%) have shown no evidence of recurrence. Results are evaluated in the light of those obtained in trials of other experimental therapies for recurrent malignant gliomas. It is concluded that the present protocol offers a safe and comparatively effective treatment option.
AuthorsM Ingram, J G Buckwalter, D B Jacques, D B Freshwater, R M Abts, G B Techy, K Miyagi, C H Shelden, R W Rand, L W English
JournalNeurological research (Neurol Res) Vol. 12 Issue 4 Pg. 265-73 (Dec 1990) ISSN: 0161-6412 [Print] England
PMID1982172 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Interleukin-2
  • Phytohemagglutinins
Topics
  • Adult
  • Aged
  • Astrocytoma (mortality, therapy)
  • Brain Neoplasms (mortality, therapy)
  • California (epidemiology)
  • Female
  • Glioblastoma (mortality, therapy)
  • Humans
  • Immunotherapy, Adoptive
  • Interleukin-2 (pharmacology)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local (mortality, therapy)
  • Phytohemagglutinins (pharmacology)
  • Survival Analysis
  • Survival Rate
  • T-Lymphocytes (drug effects, transplantation)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: